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OBJECTIVES: Approximately 250,000 patients per year are admitted to hospitals in 
the United Kingdom (UK) with skin and soft tissue (SSTI) infections, accounting for 
~1.6% of hospital admissions. Staphylococcus aureus accounts for > 50% of SSTIs; 
methicillin-resistant Staphylococcus aureus(MRSA) infections represent approxi-
mately 13.7% of those. Treatment of SSTIs is costly and often involves intravenous 
(IV) antibiotic therapy, hospitalization of ≥ 10 days and may involve both inpatient 
stay and multi-day follow-up outpatient antibiotic parenteral therapy (OPAT). 
Hospitals and healthcare systems may reduce the economic burden of hospitalized 
patients through the use of OPAT and/or early hospital discharge. Oritavancin is a 
single, once only 1200 mg IV dose for the treatment of SSTIs caused by gram posi-
tive bacteria, including MRSA. The aim of this analysis was to quantify the annual 
economic impact to a UK hospital of using oritavancin in select moderate-to-severe 
SSTI patients. METHODS: A decision tree based on current clinical practice was 
constructed to estimate the economic value of using oritavancin. Current and future 
utilization of antibiotics were informed by published literature and clinical expert 
opinion. Clinical data were derived from the literature and oritavancin’s pivotal 
phase III studies. Drug costs were derived from the British National Formulary. 
Other included costs were based on the UK 2014 NHS reference costs. RESULTS: 
For a UK hospital treating 100 SSTI patients per year eligible for IV antibiotics, using 
oritavancin conservatively (3.6% of patients) would decrease total annual cost by 
£2,922.52. Increased pharmaceutical costs (£6,111.21) were offset by reductions in 
drug administration costs (-£5,531.13) and hospitalization/OPAT costs (-£3,379.48). 
Inpatient and outpatient days of treatment were reduced by 8.2 and 16.4 days, 
respectively. CONCLUSIONS: Using oritavancin conservatively in moderate-to-
severe SSTI patients is estimated to reduce costs by £29.23/patient by shifting 
patient care to the outpatient setting, allowing for early discharge, and reducing 
hospitalization and drug administration costs.
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OBJECTIVES: Clostridium difficile infection (CDI) is a debilitating illness. In two 
phase III trials fidaxomicin produced comparable initial cure rates, significantly 
lower recurrence rates (p< 0.005) and significantly higher sustained cure rates 
(p= 0.001) versus vancomycin. This cost-effectiveness and budget impact model 
analysed the costs and outcomes of vancomycin and fidaxomicin for treatment 
of CDI in Germany. METHODS: The model was a Markov cohort simulation, with 
10-day cycle length. The analysis timescale was either 40 days (hospital perspec-
tive) or 1 year (payer perspective). Clinical inputs included : 30-day CDI-attributable 
mortality, probability of clinical cure and 30-day probability of recurrence after end 
of treatment. The first-line treatment is either Dificlir (€ 1300) or vancomycin (€ 61). 
Second line treatment is user defined, and in the base case is vancomycin. Third line 
treatment is a rescue treatment (€ 1500), assumed to have 100% cure rate. The model 
is populated with cost data for Germany. Drug costs are based on list prices, and the 
costs of hospitalisation are DRG tariff rates; Cost per day of CDI treated on a general 
ward (€ 348). A deterministic sensitivity analysis was carried out to test the robust-
ness of the model outcomes. The cost-effectiveness of six CDI patient subgroups 
was also analysed based on the two fidaxomicin clinical trials’ results. RESULTS: 
The outcomes of the model for All Patient group: incremental cost per QALY gained 
€ 40,807, cost per recurrence avoided € 2,068, and cost per bed-day saved € 110. For 
the All Patient group fidaxomicin reduced the number of recurrences by 49%. Fewer 
recurrences led to a reduction in attributable deaths, a gain in life years; an improve-
ment in quality of life; and a reduction in the number of bed-days. CONCLUSIONS: 
First-line fidaxomicin is likely to be a cost-effective treatment option, compared to 
vancomycin at a willingness to pay threshold of € 50,000 per QALY gained.
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OBJECTIVES: This research aims to assess the economic impact and cost-utility of 
replacing trivalent inactivated influenza vaccines (IIV3) with the newer influenza 
vaccines – trivalent high dose (HD) or quadrivalent (IIV4) influenza vaccine in adults 
aged 65 and older under Ontario’s Universal Influenza Immunization Program (UIIP) 
from healthcare and societal perspectives. METHODS: An analytical decision model 
was developed for the elderly (age 65-74, 75-84, and 85 and above) at two levels of 
health risks (high and low) with influenza-related health outcomes from Ontario or 
Canada. Ontario’s demographic data and labor costs were extracted from Statistics 
Canada. Vaccine efficacies were based on post-marketing clinical study for HD and 
estimated from published literatures for IIV4. Antiviral treatment and over-the-
counter medication costs were considered. Deterministic (DSA) and probabilistic 
sensitivity analyses (PSA) were conducted. Additional analysis was performed for 
long-term impact of influenza infections. RESULTS: Comparing to IIV3 under UIIP, 
IIV3 HD has a net societal budget impact of C$346,809 including premature deaths in 
a single influenza season. The incremental cost-effectiveness ratio (ICER) is C$3,763 
per QALY gained from healthcare perspective and C$190 per QALY gained from 
Canada, 3University of Calgary, Calgary, AB, Canada
OBJECTIVES: Paediatric advisory guidelines recommend prophylaxis against 
respiratory syncytial virus (RSV) for infants with hemodynamically significant 
congenital heart disease (HSCHD). However, current recommendations have 
cast doubt as to whether prophylaxis is beneficial after 1year of age. The objec-
tive of this study is to determine whether there are differences in RSV-related 
hospitalizations (RSVH) in HSCHD infants receiving palivizumab during the first 
versus second season in the Canadian Registry of palivizumab (CARESS) data-
base. METHODS: CARESS is a prospective registry of infants who have received 
≥ 1 dose of palivizumab at one of 32 sites across Canada during the 2005-2014 
RSV seasons. Demographic data were collected at enrollment and respiratory-
illness-related hospitalization events were recorded monthly. Only infants aged 
< 24 months with HSCHD were included in the analysis. RESULTS: 707 (35.1%) of 
2013 infants were prophylaxed during the second season (average age in months: 
4.7 [first season] vs 14.7 [second season]). There were no significant differences 
between first- and second-season infants in terms of baseline demographics. 
However, infants aged > 1year had a more complicated neonatal course, with sig-
nificantly longer neonatal length of stay (46.7 versus 25.6 days). 26 infants in the 
first year (RSVH rate: 2.26%) and 11 infants in the second year of prophylaxis (RSVH 
rate: 2.09%) were hospitalized. A Cox regression found that there were neither 
significant differences in hazards between infants in their first or second year of 
prophylaxis in terms of time to first RSVH nor relevant predictors of the neonatal 
course. CONCLUSIONS: Infants enrolled in the CARESS database in the second 
RSV season had a similar hazard of RSVH as those in the first year of life. These 
findings suggest that infants aged > 1 year are equally at risk for RSVH and benefit 
from palivizumab prophylaxis.
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OBJECTIVES: Pertussis (whooping cough) is an acute, highly contagious infec-
tious disease, causing uncontrollable and severe coughing. Pertussis outbreaks 
are increasingly common, but little is available on their determinants. Through a 
systematic literature review, this study aims at describing key drivers of pertussis 
outbreaks, and at listing reported recommendations. METHODS: A systematic 
review of literature on pertussis outbreaks was conducted, including references 
published between 2011 and 2014, using Medline, Embase, the Cochrane library 
and relevant websites as potential sources. All population-based studies report-
ing information about epidemiology, burden or costs of pertussis outbreaks were 
included, without geographical restriction. RESULTS: Thirty-eight observational 
studies from 14 countries were included. Three different kinds of key drivers 
were identified by authors. Disease-related drivers included delays occurring in 
diagnosis and isolation of cases, natural cyclic variations and possible pathogen-
speciﬁc changes. Healthcare management-related drivers included differences 
in physician awareness and/or underuse of laboratory diagnosis method. Finally 
booster-related drivers included low vaccination coverage and waning vaccine-
mediated immunity. Most studies attempted to provide recommendations. The 
need for vaccination campaigns was clearly stated in several studies, such as 
new vaccination strategies (vaccination of adults, maternal immunisation, ear-
lier booster dose, cocooning strategy, etc.) or more generally availability of vac-
cines providing long-lasting immunity. Systematic laboratory confirmations 
and systematic reporting were also suggested to reduce the burden of pertus-
sis. CONCLUSIONS: These results highlight the need to improve monitoring 
the epidemiology of pertussis, areas for improvement for pertussis healthcare 
management and the need to have boosters with optimal timing within the 
routine immunisation schedule. Additional research is to be carried out to sup-
port health authorities in the choice of the most adapted national vaccination 
programme.
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OBJECTIVES: HIV and AIDS is a major cause of premature death and impose a 
large socioeconomic burden in Kenya. Antiretroviral treatment (ART) is one of 
the interventions being implemented to mitigate these impacts. Studies on the 
survival rate and the socioeconomic factors explaining survival of patients on 
treatment follow up are very rare in Kenya. The objective of this research was to 
estimate the survival rate and factors associated with survival of the HIV positive 
patients on ART and those not on ART. METHODS: Baseline characteristic of adults 
on ART and those not on ART with CD4 counts 250 and below at enrolment were 
collected from the patient charts between 2003 to 2010, from Mbagathi District 
Hospital (Mbagathi) (n= 300) and Moi Teaching and Referral Hospital (Moi) in Kenya 
(n= 400). Kaplan Meier and life table analysis were used and survival durations 
measured in 3 monthly intervals. RESULTS: The survival rate declined over time. 
Approximately 3% of the patients died within the first three months of treatment 
debut and 57% were still alive at the time of this study (after 78 months of fol-
low up). 25% of the patients in Mbagathi died by the 11th cycle (33 months) (95% 
CI[7-15]) where as 25% of patients in Moi died by the 16th cycle (48 months) (95% 
CI[14-19]). In addition, after the initial 30 months of treatment follow up 77%, (95% 
CI[71.7-81.3%]) of patient enrolled in Mbagathi and 91.9%, (95% CI[88.5-94.3%]) 
enrolled in Moi were still alive, showing better survival rate of patients in Moi. 
The patients on ARVs were likely to survive longer than those not on ART, the 
female and married patients were also likely to survive longer than their male 
and unmarried counterparts. CONCLUSIONS: The study findings shows that ART 
increases the survival rates, being female and married are also associated with 
increased survival rates.
